Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

10x Genomics Honored by Goldman Sachs for Entrepreneurship – CEO Serge Saxonov Among 100 Most Intriguing Entrepreneurs at 2016 Builders + Innovators Summit

10x Genomics
Posted on: 20 Oct 16

10x Genomics, a company focused on improving and broadening the application of genomic information, announced today that Goldman Sachs is recognizing Co-Founder and Chief Executive Officer (CEO) Serge Saxonov as one of the 100 Most Intriguing Entrepreneurs of 2016 at its Builders + Innovators Summit in Santa Barbara, Calif.

Goldman Sachs selected Saxonov as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. Saxonov co-founded 10x Genomics in 2012 and has been the CEO since its inception. He has guided the company from the initial inventions, through basic R&D to full-scale commercialization. 10x has since commercialized multiple breakthrough products and established leadership positions in comprehensive genome sequencing and single cell genomics.

“We are honored to recognize Serge Saxonov as part of the most intriguing entrepreneurs of 2016,” said David Solomon, co-head of investment banking at Goldman Sachs. “This is the fifth year that we’ve hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building thriving organizations.”

For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode™ Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes, and other valuable genomic information with comprehensive workflows for Single Cell, Genome and Exome applications that incorporate their pre-existing sequencing technologies.

View source version on

Business Wire

Last updated on: 20/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.